InvestorsHub Logo
Followers 12
Posts 265
Boards Moderated 0
Alias Born 04/16/2020

Re: postes post# 288504

Wednesday, 07/29/2020 9:51:38 AM

Wednesday, July 29, 2020 9:51:38 AM

Post# of 428847
Postes,

You outlined the situation very well. We do not know what the discussions entailed. I am confident that Amarin's Legal Team and Senior Management had the same goal as you mentioned in your last post to me to do everything possible to resolve the litigation. They have a hell of a lot more riding on this than all of us combined. You cannot give away most of the value of the company just to appease and settle with two generic companies that have basically very little to lose in this litigation. Amarin has created a goldmine with this product in one, if not the largest, disease state areas in medicine and pharma. You have to look at the potential and know what the consequences would be on any unrealistic settlement the sorry generic companies are attempting to negotiate. Of course JT and Amarin wanted and still would like Hikma and Ready to go away but not by giving them most of Vascepa's potential in the US. Sometimes you have to set the bar where you feel is only reasonable and fair for everyone and if they won't accept it then you go to court with a lot of legal advantages and take your chances. I'm confident they have thought this through with great legal advice. Show some confidence with this management team. They are not doing anything different than any other pharma management team would do. I guarantee it. Have a great hump day.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News